01 1Cipla
01 1DARIFENACIN HYDROBROMIDE
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-20
Pay. Date : 2014-05-30
DMF Number : 28085
Submission : 2014-05-02
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is DARIFENACIN HYDROBROMIDE, with a corresponding US DMF Number 28085.
Remarkably, this DMF maintains an Active status since its submission on May 02, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 20, 2014, and payment made on May 30, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II
